Lead Program Lead candidate intranasal foralumab in Phase 2a for na-SPMS positions the company in neuroimmunology and MS-related therapies, presenting cross-sell opportunities to partners or CROs with neurodegenerative disease portfolios and potential expansion into other autoimmune indications.

Clinical Momentum Recent clinical activity and upcoming conference participation (World Parkinson Congress, Neuroscience Innovation Forum, BIO-Europe) create multiple touchpoints for outreach to investors, potential collaborators, and contract research organizations seeking late-stage or near-term trial collaborations.

Strategic Partners Active engagement with industry events and a focus on immunomodulation therapies, including anti-CD3 and IL-6R programs, suggests opportunities to align with pharma players seeking novel immunotherapy modalities or combination therapy strategies.

Global Outreach Presence on Nasdaq, international press coverage, and events across Europe and North America indicate a readiness to engage global pharma and biotech partners, licensing discussions, or co-development deals to accelerate development and commercialization.

Revenue Levers Current revenue in the low-to-mid single digits with a strong IP-driven pipeline and lead candidate focus implies opportunities for collaboration on funded trials, milestone-based agreements, or sponsored research with larger biotech companies seeking immunotherapy capabilities.